TNF and hidradenitis suppurativa: Both diseases have been shown to respond to TNF-α antibodies (including infliximab and Adalizumab) involving inflammatory pathways involving IL-23 and Th-17 that have been linked to hidradenitis suppurativa and Crohn’s disease (Abraham and Cho, 2009; Schlapbach et al., 2011).